SEC Form 4 · accession 0001144204-16-104313
Cellectar Biosciences, Inc. · CLRB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James V Caruso
Officer — President and CEO · Director
Period of report
May 12, 2016
Accepted (ET)
May 23, 2016 · 7:42 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001279704
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $1.48 | May 12, 2016 | A | 200,000 | A | — | May 12, 2026 | Common Stock | 200,000 | 237,500 | D |
Explanation of responses
- F1Options are not exercisable until stockholder approval of the increase of shares available for issuance under the plan. Options vest in equal quarterly increments over a period of three years from the date of grant.